Among cases with outcome data, the average maternal and gestational ages were 35.3 years and 13.9 weeks, respectively; average fetal fraction was 11.4%. PPVs were 95.2% (T21), 93.5% (T18), 77.9% (T13), and 86.7% (MX)-consistent with or higher compared with previous published reports 1 (Table 1) . CONCLUSION: This study demonstrates that a laboratory driven, quality assurance program can monitor test performance for noninvasive prenatal screening for aneuploidy. The PPV of NIPT has been the subject of much speculation, however, these data suggest that PPVs are congruent with previous publications and may even be higher than previously reported for T21, T18, T13, and MX.
1 Prospective monitoring of the performance of a laboratory test, or "quality assurance," is the responsibility of a clinical molecular laboratory; the 44.1% follow-up rate for high-risk calls reflects dedication of both laboratory genetic counselors and the obstetrical care providers the laboratory serves. These data demonstrate a successful collaboration between laboratory, genetic counselor, and provider and detail critical information about SNP-based NIPT performance in a general unselected population that, in turn, can enable providers to more accurately counsel patients.
930 Clinical utility of non-invasive prenatal screening for common dominant monogenic disorders 
OBJECTIVE:
The discovery of circulating cell-free fetal DNA (ccfDNA) in maternal blood has allowed the development of noninvasive prenatal screening (NIPS) techniques to detect fetal genetic abnormalities. We have developed a 30-gene panel NIPS test for common dominant monogenic disorders with a cumulative incidence comparable to that of common aneuploidies and a similar range of adverse outcomes. We present our clinical experience with this test on >400 pregnancies at moderate to high-risk. STUDY DESIGN: We retrospectively reviewed the test results from 403 plasma samples sent to our laboratory for screening with the singlegene NIPS test. Samples were collected from women with singleton pregnancies with: 1) abnormal fetal ultrasound findings (35.7%, 144/403); 2) family history of relevant or other genetic diseases (8.2%, 33/403); 3) advanced parental age (56.1%, 226/403). Groups 1 and 2 were classified as high-risk, while group 3, advanced maternal age (AMA) 3 35 yr or advanced paternal age (APA) 3 40 yr, was classified as moderate risk. The gestational age (GA) ranged from 9 to 36.6 weeks (average 16.8 weeks). Based on our test clinical sensitivity, specificity, negative predictive value and positive predictive value, a decision-analytic model was used to calculate costs and outcomes for women screened for single gene disorders. Cumulative incidence of the diseases and lifetime costs of an affected child were derived from the literature. RESULTS: Pathogenic or likely pathogenic sequence variants were detected in 18.5% (27/144) of cases with abnormal fetal ultrasound and in 12.1% (4/33) of cases with a positive family history (all four positive cases were with affected fathers). All positive findings were in the high-risk groups (31/177, 17.5%) while no positive findings were detected in the moderate-risk groups. The clinical positive predictive value was >99% in the high-risk population. Using these data to model the detection rate in a theoretical cohort of 4 million women (the total number of pregnancies at 12 weeks GA in the US), support a potential diagnosis of 6,667 affected fetuses (including stillbirth and neonatal death) given a cumulative incidence of these disorders estimated at 1/600. CONCLUSION: Our study supports the clinical utility for our 30-gene panel NIPS test for common dominant monogenic disorders in the high-risk population. 
